ZA201707998B - Injectable pharmaceutical formulations of lefamulin - Google Patents

Injectable pharmaceutical formulations of lefamulin

Info

Publication number
ZA201707998B
ZA201707998B ZA2017/07998A ZA201707998A ZA201707998B ZA 201707998 B ZA201707998 B ZA 201707998B ZA 2017/07998 A ZA2017/07998 A ZA 2017/07998A ZA 201707998 A ZA201707998 A ZA 201707998A ZA 201707998 B ZA201707998 B ZA 201707998B
Authority
ZA
South Africa
Prior art keywords
lefamulin
pharmaceutical formulations
injectable pharmaceutical
injectable
formulations
Prior art date
Application number
ZA2017/07998A
Inventor
Mathias Ferencic
Werner Heilmayer
Peter Hinsmann
Wolfgang Wicha
Original Assignee
Leberstasse 20
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leberstasse 20 filed Critical Leberstasse 20
Publication of ZA201707998B publication Critical patent/ZA201707998B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2017/07998A 2015-06-17 2017-11-24 Injectable pharmaceutical formulations of lefamulin ZA201707998B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562180871P 2015-06-17 2015-06-17
PCT/EP2016/063609 WO2016202788A1 (en) 2015-06-17 2016-06-14 Injectable pharmaceutical formulations of lefamulin

Publications (1)

Publication Number Publication Date
ZA201707998B true ZA201707998B (en) 2021-04-28

Family

ID=56131530

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/07998A ZA201707998B (en) 2015-06-17 2017-11-24 Injectable pharmaceutical formulations of lefamulin

Country Status (27)

Country Link
US (1) US12121582B2 (en)
EP (1) EP3310331B1 (en)
JP (1) JP6818019B2 (en)
KR (1) KR102656841B1 (en)
CN (1) CN107810000B (en)
AU (1) AU2016278774C1 (en)
BR (1) BR112017026904B1 (en)
CA (1) CA2989372C (en)
CY (1) CY1123722T1 (en)
DK (1) DK3310331T3 (en)
EA (1) EA033988B1 (en)
ES (1) ES2843723T3 (en)
HK (1) HK1252534A1 (en)
HR (1) HRP20210010T1 (en)
HU (1) HUE053024T2 (en)
IL (1) IL256115A (en)
LT (1) LT3310331T (en)
MX (1) MX2017015812A (en)
PH (1) PH12017502319A1 (en)
PL (1) PL3310331T3 (en)
PT (1) PT3310331T (en)
RS (1) RS61327B1 (en)
SI (1) SI3310331T1 (en)
TW (1) TWI718158B (en)
UA (1) UA121240C2 (en)
WO (1) WO2016202788A1 (en)
ZA (1) ZA201707998B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202203907A (en) 2020-04-17 2022-02-01 奧地利商納畢瓦治療有限責任公司 Novel therapeutic use of pleuromutilins
WO2021209596A1 (en) * 2020-04-17 2021-10-21 Nabriva Therapeutics GmbH Therapeutic use of pleuromutilins
EP4135682A1 (en) 2020-04-17 2023-02-22 Nabriva Therapeutics GMBH Therapeutic use of pleuromutilins
CN117677709A (en) * 2021-07-19 2024-03-08 Jbs科学有限公司 Method for separating circulating DNA from urine sample
WO2023152115A1 (en) 2022-02-09 2023-08-17 Nabriva Therapeutics GmbH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130709A (en) 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
BE1003647A5 (en) * 1989-02-28 1992-05-12 Syntex Inc PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION PARENTERAL nicardipine.
DE4023848C2 (en) 1990-07-27 1994-04-21 Huels Chemische Werke Ag Process for the preparation of 3-C¶1¶ to C¶6¶-Alkoxycarbonylcyclohexanpropionsäureestern
FR2772272B1 (en) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITIONS BASED ON DALFOPRISTINE AND QUINUPRISTINE AND THEIR PREPARATION
US6187746B1 (en) 1997-12-16 2001-02-13 Rhone-Poulenc Rorer S.A. Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof
MXPA02009816A (en) 2000-04-04 2003-03-27 Smithkline Beecham Plc 2-hydroxy-mutilin carbamate derivatives for antibacterial use.
GB0017031D0 (en) 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
GB0207495D0 (en) 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
NZ555982A (en) * 2004-12-30 2011-01-28 Astex Therapeutics Ltd Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
EP2298733B1 (en) 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GB0515995D0 (en) 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP2159220A1 (en) * 2008-09-02 2010-03-03 Nabriva Therapeutics AG Organic compounds
WO2011002776A1 (en) * 2009-06-29 2011-01-06 Nitric Biotherapeutics, Inc. Pharmaceutical formulations for iontophoretic delivery of an immunomodulator
EP2399904A1 (en) 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (en) * 2012-01-17 2014-10-01 北京艾百诺科技有限公司 Mulin acetate comprising substituted squaric acid, and application thereof
CN103626693B (en) * 2012-08-28 2016-09-14 中国科学院上海药物研究所 One class pleuromutilin derivative, its pharmaceutical composition and synthetic method thereof and purposes
JP6533780B2 (en) * 2013-05-28 2019-06-19 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー Combination therapy comprising oxazolidinone-quinolones for use in the treatment of bacterial infections
TWI762573B (en) * 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 Purification of pleuromutilin

Also Published As

Publication number Publication date
KR20180030479A (en) 2018-03-23
IL256115A (en) 2018-02-28
MX2017015812A (en) 2018-07-06
US20180360966A1 (en) 2018-12-20
EP3310331A1 (en) 2018-04-25
DK3310331T3 (en) 2021-01-11
HRP20210010T1 (en) 2021-03-05
JP6818019B2 (en) 2021-01-20
TWI718158B (en) 2021-02-11
EP3310331B1 (en) 2020-10-14
CY1123722T1 (en) 2022-05-27
RS61327B1 (en) 2021-02-26
PT3310331T (en) 2021-01-19
AU2016278774C1 (en) 2021-11-18
CN107810000A (en) 2018-03-16
UA121240C2 (en) 2020-04-27
JP2018517777A (en) 2018-07-05
KR102656841B1 (en) 2024-04-12
AU2016278774B2 (en) 2021-07-29
BR112017026904B1 (en) 2023-10-10
EA201890075A1 (en) 2018-05-31
CA2989372C (en) 2023-10-03
HK1252534A1 (en) 2019-05-31
CA2989372A1 (en) 2016-12-22
CN107810000B (en) 2021-03-12
TW201716056A (en) 2017-05-16
WO2016202788A1 (en) 2016-12-22
LT3310331T (en) 2021-01-11
HUE053024T2 (en) 2021-06-28
AU2016278774A1 (en) 2017-12-07
PL3310331T3 (en) 2021-04-19
PH12017502319A1 (en) 2018-06-25
EA033988B1 (en) 2019-12-17
ES2843723T3 (en) 2021-07-20
US12121582B2 (en) 2024-10-22
SI3310331T1 (en) 2021-02-26
BR112017026904A2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
HK1243650A1 (en) Pharmaceutical compositions comprising meloxicam
IL287947A (en) Reducing viscosity of pharmaceutical formulations
SI4070788T1 (en) Pharmaceutical formulations
HK1254343A1 (en) Pharmaceutical formulations
HK1252534A1 (en) Injectable pharmaceutical formulations of lefamulin
ZA201707094B (en) Pharmaceutical formulations
IL267279A (en) Pharmaceutical formulations of suvorexant
HK1245073A1 (en) Pharmaceutical compositions
ZA201705329B (en) Pharmaceutical formulations of racecadotril
IL252729A0 (en) Injectable formulations of paracetamol
PL3319596T3 (en) Pharmaceutical compositions
GB201506598D0 (en) Pharmaceutical compositions